Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 11, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Executive Supplemental Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
Changes in share interests were reported for two individuals due to the re-investment of dividends paid on April 10, 2008, at a price of $43.84 per ADR:
- Dr J P Garnier: Increase of 596.14 ADRs.
- Dr D Pulman: Increase of 32.12 ADRs.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of director shareholdings in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the dividend payment date of April 10, 2008, and the re-investment price of $43.84 per ADR.
- Confirm the updated total shareholdings for Dr J P Garnier and Dr D Pulman following these specific transactions.
- Note that this filing does not contain financial performance data for the period.